Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,644,530
  • Shares Outstanding, K 61,358
  • Annual Sales, $ 78,590 K
  • Annual Income, $ -146,960 K
  • 60-Month Beta 2.22
  • Price/Sales 34.20
  • Price/Cash Flow N/A
  • Price/Book 3.78
Trade KYMR with:

Options Overview Details

View History
  • Implied Volatility 77.64% ( +4.03%)
  • Historical Volatility 87.67%
  • IV Percentile 42%
  • IV Rank 30.37%
  • IV High 169.84% on 10/20/23
  • IV Low 37.42% on 07/21/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 68
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 1,646
  • Open Int (30-Day) 1,308

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.69
  • Number of Estimates 12
  • High Estimate -0.41
  • Low Estimate -0.81
  • Prior Year -0.67
  • Growth Rate Est. (year over year) -2.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.24 +47.40%
on 06/28/24
48.70 -11.50%
on 07/16/24
+11.90 (+38.14%)
since 06/18/24
3-Month
29.24 +47.40%
on 06/28/24
48.70 -11.50%
on 07/16/24
+9.13 (+26.88%)
since 04/19/24
52-Week
9.60 +348.96%
on 11/02/23
48.70 -11.50%
on 07/16/24
+21.26 (+97.34%)
since 07/19/23

Most Recent Stories

More News
S&P Futures Tick Higher Ahead of Powell’s Testimony, U.S. Inflation Data and Earnings Awaited

September S&P 500 E-Mini futures (ESU24) are trending up +0.15% this morning as investors looked ahead to further testimony from Federal Reserve Chair Jerome Powell while also bracing for Thursday’s...

ESU24 : 5,577.75 (+0.43%)
PFG : 84.71 (-0.74%)
NVDA : 117.93 (-2.61%)
KYMR : 43.10 (-1.60%)
ALB : 92.09 (-1.83%)
JPM : 209.78 (-0.10%)
WFC : 59.23 (-0.02%)
C : 65.14 (+0.39%)
KOG.O.DX : 1,072.000 (+1.04%)
VVPR : 2.75 (+7.00%)
AEHR : 19.03 (+1.06%)
SGH : 23.86 (-3.17%)
Assured Guaranty, Kymera rise; BP, Helen of Troy fall, Tuesday, 7/9/2024

Stocks that traded heavily or had substantial price changes on Tuesday: Assured Guaranty, Kymera rise; BP, Helen of Troy fall

HLIO : 44.07 (-2.61%)
ACLS : 127.96 (-4.57%)
WULF : 5.59 (+4.49%)
APLD : 5.72 (+0.70%)
HELE : 56.75 (-4.54%)
KYMR : 43.10 (-1.60%)
AGO : 79.47 (-2.05%)
Why Kymera Therapeutics Stock Is Soaring Today

Kymera's lead pipeline candidate received some good news.

KYMR : 43.10 (-1.60%)
Stock Index Futures Inch Higher Ahead of Powell’s Testimony

September S&P 500 E-Mini futures (ESU24) are up +0.16%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.27% this morning as market participants awaited Federal Reserve Chair Jerome Powell’s...

ESU24 : 5,577.75 (+0.43%)
NQU24 : 19,850.00 (+0.69%)
GLW : 44.31 (-1.51%)
INTC : 32.98 (-5.42%)
AMD : 151.58 (-2.69%)
MORF : 56.52 (+0.36%)
NKE : 72.70 (+0.44%)
JPM : 209.78 (-0.10%)
WFC : 59.23 (-0.02%)
C : 65.14 (+0.39%)
DSY.FP : 34.360 (-0.29%)
BP-.LN : 456.168 (-0.25%)
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END

ONCY : 1.0300 (unch)
ONC.TO : 1.41 (+0.71%)
KYMR : 43.10 (-1.60%)
RHHBY : 39.2700 (-0.18%)
GILD : 72.56 (-1.29%)
AMGN : 331.29 (+0.10%)
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

ONCY : 1.0300 (unch)
ONC.TO : 1.41 (+0.71%)
KYMR : 43.10 (-1.60%)
RHHBY : 39.2700 (-0.18%)
GILD : 72.56 (-1.29%)
AMGN : 331.29 (+0.10%)
Why Shares of Kymera Therapeutics Jumped on Tuesday

The company had a big bounce after hitting a 52-week low the day before.

SNY : 50.62 (+0.52%)
KYMR : 43.10 (-1.60%)
Join These Motley Fool Investors for "The Market Cap Game Show"

Multiplying the number of shares by the share price is just step one.

ASML : 895.37 (-3.11%)
AMZN : 183.13 (-0.34%)
MELI : 1,649.99 (+1.65%)
ETSY : 62.76 (-1.41%)
PYPL : 59.33 (-1.12%)
CELH : 49.58 (-2.75%)
KYMR : 43.10 (-1.60%)
MA : 443.69 (-1.12%)
BOC : 13.61 (-1.02%)
PCOR : 68.25 (+1.56%)
WMT : 70.75 (-0.10%)
X-Chem and Kymera Expand Existing Partnership

X-Chem , the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc. (NASDAQ: KYMR). With the expanded...

KYMR : 43.10 (-1.60%)
Delta, Kymera rise; Charter, ABM Industries fall

Stocks that traded heavily or had substantial price changes Wednesday: Delta, Kymera rise; Charter, ABM Industries fall

ABM : 53.59 (-0.32%)
VSAT : 15.41 (-3.81%)
DAL : 45.44 (+1.16%)
CHTR : 320.31 (-0.41%)
MSFT : 437.11 (-0.74%)
KYMR : 43.10 (-1.60%)
LII : 555.76 (+0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 46.30
2nd Resistance Point 45.49
1st Resistance Point 44.30
Last Price 43.10
1st Support Level 42.30
2nd Support Level 41.49
3rd Support Level 40.30

See More

52-Week High 48.70
Last Price 43.10
Fibonacci 61.8% 33.76
Fibonacci 50% 29.15
Fibonacci 38.2% 24.54
52-Week Low 9.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar